Spots Global Cancer Trial Database for Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma
Official Title: A Phase 2 Proof of Concept Study to Evaluate the Efficacy, Safety and Pharmacokinetics of the HDAC Inhibitor 4SC-201 in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Study ID: NCT01037478
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to determine whether Resminostat (4SC-201) is effective and safe in the treatment of relapsed or refractory Hodgkin's Lymphoma.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Fakultní nemocnice Brno, Brno, , Czech Republic
Fakultní nemocnice Hradec Kralové, Hradec Kralové, , Czech Republic
Fakultní nemocnice Kralovske Vinohrady, Praha, , Czech Republic
Uniwersyteckie Centrum Kliniczne, Gdańsk, , Poland
Samodzielny Publiczny Szpital Kliniczny Nr.1 w Poznaniu, Poznan, , Poland
Instytut im. Marii Sklodowskiej-Curie, Centrum Onkologii, Warsaw, , Poland
Wojskowy Instytut Medyczny, Warsaw, , Poland
Samodzielny Publiczny Szpital Kliniczny Nr.1 we Wroclawiu, Wroclaw, , Poland
Institutul Clinic Fundeni, Bucharest, , Romania
Spitalul Clinic Coltea, Bucharest, , Romania
Contact Details
Name: Jan Walewski, Prof.
Affiliation: Instytut im. Marii Skłodowskiej-Curie, Centrum Onkologii, Warsaw, Poland
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
